+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Pitching Respiratory Innovation QuickFire Challenge

Johnson & Johnson

Overview

To identify innovations that may address multiple disease-driving pathways related to immune-mediated inflammatory diseases, Johnson & Johnson is proud to launch the Pitching Respiratory Innovation QuickFire Challenge. Innovators worldwide are invited to submit ideas to target novel pathways or approaches with the potential to deliver treatments for patients living with Asthma and/or Chronic Obstructive Pulmonary Disease (COPD) with a particular focus on non-type 2 (non-T2) mechanisms.

Selected applicants will have the opportunity to showcase their science to a panel of Johnson & Johnson Innovative Medicine Immunology leaders in a closed-door virtual pitch in late August.*

Despite advances in respiratory science, patients with Asthma and COPD — particularly those whose conditions are driven by non-T2 inflammatory pathways — may have limited or could benefit from more advanced treatment options.1 Research suggests that targeting these alternative pathways could unlock novel therapeutic strategies capable of addressing the unmet needs of these individuals.2

* Subject to terms and conditions of applicable QuickFire Challenge
1 Barnes, P. J. Allergy 74, 1249–1256 (2019).
2 Sze, E. et al. Allergy 75, 311–325 (2020).

Why this challenge matters to us

At Johnson & Johnson, we are committed to delivering transformational therapies for people living with immune-mediated inflammatory diseases. This challenge reflects our dedication to identifying novel scientific approaches that can help expand treatment options and improve care for patients with Asthma and COPD—particularly those whose needs remain unmet by current therapies.

What we’re looking for

Innovators worldwide are invited to submit ideas to target novel pathways or approaches with the potential to deliver treatments for patients living with Asthma and/or Chronic Obstructive Pulmonary Disease (COPD) with a particular focus on non-type 2 (non-T2) mechanisms.

Special consideration will be given to submissions with proof-of-concept data and preclinical or asset-stage programs with in vitro/in vivo validation.

Research approaches that are not within scope for this challenge include:

Inhaled drug delivery approaches
Cystic fibrosis (genetic defect-targeting) therapies
Antibiotic-based strategies for chronic bronchitis
Alpha-1 antitrypsin deficiency therapies
Drug repurposing

Awards

Selected applicants will have the opportunity to showcase their science to a panel of Johnson & Johnson Innovative Medicine Immunology leaders in a closed-door virtual pitch in late August.*

*Subject to terms and conditions of applicable QuickFire Challenge

Timeline

May 16, 2025

Launch

July 11, 2025

Application deadline

Late August 2025

Virtual pitch opportunity

AI Based Application Success Predictor

🎯 1. Alignment with Strategic Focus & Unmet Medical Needs

Whether you're applying to QuickFire Challenges, JLABS residency, or disease-specific innovation grants, your proposal must address a clear, unmet clinical or market need in areas J&J prioritizes (e.g., oncology, metabolic disorders, health equity) 

Applications should directly link to J&J’s health equity, prevention, interception, or cure strategies

🌟 2. Transformational Innovation with Clear Milestones

J&J favors transformative science or technology that is not just innovative but also scalable and impactful 

Judges want a 12–18 month project plan with concrete deliverables and clear “time-to-market” goals 

👥 3. Strong Team & Institutional/Diverse Partnerships

Show a solid team with relevant expertise, including leadership, technical competence, and financial capacity 

For Innovation Grants or disease-specific awards (e.g., AACR-J&J Lung Cancer Grants), multi-institutional teams (2–3 PIs across institutions) with clinical components are required .

Health Equity and Veterans Challenges emphasize lived experience and team alignment with communities.

💰 4. Realistic Budgeting & Use of Funds

Provide transparent, justified budgets—QuickFire grants typically cap at US $250–500K, with higher-end provided via programs like JLABS + QuickFire .

Expect documentation of funding sources, existing partnerships, and financial solvency .

🏢 5. Access to Ecosystem (JLABS & Mentorship)

Many awards offer residency at JLABS, mentorship, and ecosystem access—but applicants must demonstrate readiness for such integration .

The offering includes capital-efficient lab space and entrepreneurship support 

🧠 6. Clear Go-to-Market/Implementation Plan

Competitive proposals detail key milestones, scalability strategy, and time-to-market within a short timeframe .

Strong plans also outline clinical validation components, especially for oncology or therapeutic innovations 

🔎 7. External/Peer-Led Selection & Community Input

Evaluation panels often include external experts, including subject-matter specialists and community stakeholders .

Community-based challenges emphasize lived experience with reviewers assessing feasibility, impact, team quality, and scalability.

📋 Quick Reference Summary

Success Factor	Action Items
Strategic alignment	Map proposal to J&J priorities & clinical gaps
Innovation & milestone focus	Emphasize transformative potential & timeline
Team strength	Showcase leadership, partnerships, and experience
Budget clarity	Detail use of funds and funding sources
Ecosystem integration	Demonstrate fit for JLABS and mentorship support
Implementation plan	Define next steps, go-to-market, and validation
Peer/external review readiness	Prepare for scrutiny by experts and communities

🛠️ Pro Tips

Choose a fitting grant stream: QuickFire, disease-specific, health equity, or veterans initiatives.

Highlight unmet clinical or market need directly related to J&J’s innovation priorities.

Assemble a team early: consider cross-institutional and community-led collaborations.

Develop a detailed 12–18 month roadmap with milestones and go-to-market strategies.

Prepare a realistic, justified budget—including current funding and financial stability.

Engage with JLABS network early, showing readiness for incubation and mentorship.

Submit polished, non-confidential documentation—formatted to J&J’s application templates.

Tailor to reviewers: include both scientific experts and representatives of target communities.

Specialties

Immunology

Eligibility Requirements

Potential solutions will be evaluated by a panel of reviewers on their ability to meet the following criteria:

Strategic alignment or relevance to non-T2 inflammatory pathways in Asthma and COPD
Differentiation of asset profile or validated platform for novel target identification
Feasibility of development of the asset
Demonstration of safety and efficacy through clinical or preclinical proof-of-concept data
Identification of key resources and a plan to further the idea
Team expertise and capabilities

Sponsor Details

Sponsor Institute/Organizations: Johnson & Johnson

Sponsor Type: Corporate/Non-Profit

Address: New Brunswick, New Jersey, USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity